Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Conditions
Primary Myelofibrosis (PMF) · Post Polycythemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
Contact: Principal Investigator (Harinder Gill, MD)
Study leads
Harinder Gill, MD
Principal Investigator
The University of Hong Kong